EPIC-STEMI

Issue: November 2022

Fact checked byRichard Smith

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Treatment effect of the PCSK9 inhibitor alirocumab (Praluent, Sanofi/Regeneron) vs. sham control on LDL in patients with STEMI referred for primary PCI.